Catumaxomab

also known as Removab

Developed for: ovarian cancer · peritoneal neoplasm · carcinoma · gastric adenocarcinoma · malignant epithelial tumor of ovary · fallopian tube neoplasm · gastric neoplasm · gastroesophageal junction adenocarcinoma
+4 more
· peritoneal carcinoma · peritoneal carcinomatosis · urinary bladder cancer · urinary bladder neoplasm
Investigated by: Neovii Biotech · Fresenius Biotech North America · LintonPharm Co.,Ltd. · AGO Study Group · AIO-Studien-gGmbH · Gustave Roussy, Cancer Campus, Grand Paris
+3 more
· JSehouli · Lindis Biotech GmbH · Spanish Ovarian Cancer Research Group

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Removab	—	2009-04-20	europa.eu ↗

Trials 15

today

EU approved 2009

NCT04799847 · Ph 1/2 NCT04222114 · Ph 3 NCT04819399 · Ph 1 NCT01815528 · Ph 2 NCT01784900 · Ph 2 NCT01504256 · Ph 2 NCT01320020 · Ph 1 NCT01246440 · Ph 2 NCT01065246 · Ph 2 NCT00822809 · Ph 3 NCT00563836 · Ph 2 NCT00377429 · Ph 2 NCT00352833 · Ph 2 NCT00326885 · Ph 2 NCT00189345 · Ph 2

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 12 trials
Phase 1	NCT04819399	Jul 2020 → Dec 2022	urinary bladder neoplasm	Lindis Biotech GmbH	Unknown	No outcome recorded
Phase 1	NCT01320020	Feb 2011 → Mar 2013	carcinoma	Neovii Biotech	Terminated	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT04799847	Nov 2021 → Nov 2024	urinary bladder cancer	LintonPharm Co.,Ltd.	Unknown	No outcome recorded
Phase 210 trials
Phase 2	NCT01815528	Mar 2013 → Feb 2014	malignant epithelial tumor of ovary	JSehouli	Completed	No outcome recorded
Phase 2	NCT01784900	Nov 2012 → Jan 2016	peritoneal carcinomatosis	Gustave Roussy, Cancer Campus, Grand Paris	Terminated	No outcome recorded
Phase 2	NCT01504256	Oct 2011 → Mar 2017	gastric adenocarcinoma, gastroesophageal junction adenocarcinoma	AIO-Studien-gGmbH	Completed	No outcome recorded
Phase 2	NCT01246440	Jun 2010 → Feb 2014	ovarian cancer	Spanish Ovarian Cancer Research Group	Completed	No outcome recorded
Phase 2	NCT01065246	Nov 2009 → Apr 2011	peritoneal carcinoma	Neovii Biotech	Completed	No outcome recorded
Phase 2	NCT00563836	Nov 2007 → Sep 2008	malignant epithelial tumor of ovary	Neovii Biotech	Completed	No outcome recorded
Phase 2	NCT00377429	Sep 2006 → Feb 2008	ovarian cancer	Neovii Biotech	Completed	No outcome recorded
Phase 2	NCT00352833	Jul 2006 → Sep 2007	gastric adenocarcinoma	Neovii Biotech	Completed	No outcome recorded
Phase 2	NCT00326885	Jun 2006 → Dec 2009	peritoneal neoplasm	Neovii Biotech	Completed	No outcome recorded
Phase 2	NCT00189345	May 2004 → Oct 2005	fallopian tube neoplasm, ovarian cancer, peritoneal neoplasm	AGO Study Group	Completed	No outcome recorded
Phase 32 trials
Phase 3	NCT04222114	Oct 2020 → Mar 2023	gastric neoplasm	LintonPharm Co.,Ltd.	Unknown	No outcome recorded
Phase 3	NCT00822809	Dec 2008 → Nov 2010	carcinoma, peritoneal neoplasm	Neovii Biotech	Completed	No outcome recorded
Comparator or background therapy2 trials
Phase 2	NCT00464893 Comparator	Apr 2007 → Apr 2009	gastric adenocarcinoma	Neovii Biotech	Completed	No outcome recorded
Phase 2/3	NCT00836654 Comparator	Sep 2004 → Nov 2006	peritoneal neoplasm	Neovii Biotech	Completed	No outcome recorded

Press releases naming this drug 1 release

Date	Issuer	Release
2011-01-27	Sobi, Inc.	Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab® sobi.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 19 sources stand behind the page.

Field	Value	Cited text
Known as	Catumaxomab	“trifunctional bispecific antibody Catumaxomab” PMID 21733566 ↗ Jul 2011 16 NCT00836654 ↗ NCT00326885 ↗ NCT01784900 ↗ NCT00563836 ↗ NCT01504256 ↗ NCT01815528 ↗ NCT04799847 ↗ NCT01246440 ↗ NCT04222114 ↗ NCT04819399 ↗ Show 6 more sources
Known as	Removab	ChEMBL registry synonym — accepted as the source's own label CHEMBL2108581 ↗
Action	Activate	“catumaxomab infusion activates NK cells and macrophages in addition to T cells” PMID 26049121 ↗ Jun 2015
Modality	Monoclonal antibody	“Catumaxomab is a trifunctional antibody targeting EpCAM on tumor cells and CD3 on T cells.” NCT00326885 ↗
Route	Other	“6-hour intraperitoneal infusion on days 0, 3, 7 and 10” PMID 21733566 ↗ Jul 2011
Target	EPCAM	“Epithelial cell adhesion molecule cross-linking agent” CHEMBL2108581 ↗